Kun Zhou

Scientist @ GSK

About

• More than 10 years of sceintific experience with 3 years in pharmaceutical/biotech companies. • An in-depth knowledge in cancer biology, immunology, immune-oncology, in vitro (Cell-culture) and in vivo (cancer and infectious diseases) model establishment and RNA medicines. • Excel at understanding complex scientific information and delivering concise and lucid technical information to individuals and groups. • Highly skilled with wet laboratory techniques such as cell culture, Western Blot, Flow cytometry, ELISA, Luminex, MSD, qPCR, RNA scope, ELISPOT, etc... • Excellent team leader with strong problem-solving, troubleshooting, oral and written communication skills.

Country

United States

City

Watertown

Industry

Research

Skill

In vivo immunology, small RNA, tRNA fragment, RNAseq Analysis, Biomarker Discovery, immuno oncology, Small Molecules, Mechanism Of Action Studies, in vivo disease model, vaccine development, Project Management, Multi-color Flow Cytometry, Immunoassays, Cancer Research, Molecular & Cellular Biology, CRISPR knock-out, Tissue Culture, Molecular Biology, Western Blotting, Biochemistry

Experience

Scientist

GSK

2024-12 - Present · 1 yr 10 mos

Cambridge, Massachusetts, United States

Project Leader/Investigator-RNA medicine

GeneLeap Biotechnology

2021-11 - 2024-12 · 3 yrs 2 mos

Woburn, Massachusetts, United States

• Project lead for the HPV mRNA therapeutic cancer vaccine program • Successfully built the mRNA medicine portfolios from early discovery to program nomination across multiple disease areas • Project lead for an adjuvant discovery program (Oligonucleotide therapy platform) • Mentored and supervised junior scientists for routine bench work • Managed various CROs for preclinical pharmacology studies and led communications across internal teams, such as process development team and LNP manufacturing team.

Postdoctoral Research Fellow

Boston Children's Hospital

2017-10 - 2021-11 · 4 yrs 2 mos

Greater Boston Area

• Conducted state-of-the-art mechanism of action study of novel soluble benzimidazole derivative that preferentially target late-stage tumors and drug-resistant tumors (e.g., AR-V7 enriched prostate cancer). • Developed strategies of co-delivering tumor suppressor mRNA and oncogenes siRNAs/chemotherapy drugs/immunotherapy drugs to tumor cells and validated their anti-tumor efficiency in multiple models. • Establishing nanoparticle mediated in vivo CRISPR screens in multiple cancers (e.g. colon cancer, breast cancer and medulloblastoma) to identify novel oncogenes and tumor suppressors • Led and secured a material transfer agreement on novel soluble benzimidazole derivative with biotech company.

Research assistant

University of Minnesota

2012-8 - 2017-9 · 5 yrs 2 mos

Duluth, Minnesota Area

• Developed novel method of small RNA deep sequencing on liquid biopsies from ovarian cancer patients. • Identified and analyzed small noncoding RNAs from urine as potential cancer biomarker. • Characterized a novel microRNA-like tRNA fragment and revealed its functions in ovarian cancer cells. • Excellent written and oral communications skills demonstrated by three publications and 10+ regional/national presentations.